article thumbnail

Eli Lilly, Pfizer, Merck among Big Pharma losers in China's latest round of procurement bidding

The Pharma Data

Companies such as AstraZeneca, Sanofi and Eli Lilly have managed to keep business under the aggressive procurement program, but they had to live with major discounts. . It’s not a completely unforeseen shift, though. Pfizer’s established drugs business started showing a decline in China back in April 2019.

article thumbnail

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies.

Marketing 257